Human Immunodeficiency Virus Preexposure Prophylaxis in Adolescents and Young Adults

Abstract

Human immunodeficiency virus (HIV) prevention holds the promise of decreasing the burden of HIV infections worldwide. Access to HIV prevention services, including preexposure prophylaxis (PrEP), is a key strategy in reducing HIV transmission, but it continues to be underused. PrEP, a once-daily medication for HIV prevention, is approved for adolescents. A pediatrician's role is critical in identifying and increasing access for adolescents and young adults to PrEP services and reducing HIV acquisition in youth.